CLAIMS

1. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]:



[I]

(wherein R^1 and R^2 are the same or different, and independently are hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl, C_{1-6}alkoxy-C_{1-6}alkyl, hydroxy-C_{1-6}alkyl, cyano-C_{1-6}alkyl, carbamoyl-C_{1-6}alkyl or di(C_{1-6}alkyl)amino-C_{1-6}alkyl, cyano, carbamoyl or aryl;

R^3 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-6}alkyl, halogen, C_{1-6}alkoxy, C_{3-7}cycloalkyloxy, C_{1-6}alkylthio or $-N(R^6)R^7$;

R^4 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl or C_{3-7}cycloalkyl-C_{1-6}alkyl;

R^5 is hydrogen, C_{1-6}alkyl, aryl-C_{1-6}alkyl or carbamoyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkylthio, C_{1-6}alkylsulfinyl, C_{1-6}alkylsulfonyl, cyano, nitro, hydroxy, $-CO_2R^8$, $-C(=O)R^9$, $-CONR^{10}R^{11}$, $-OC(=O)R^{12}$, $-NR^{13}CO_2R^{14}$, $-S(=O)_rNR^{15}R^{16}$, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and $-N(R^{17})R^{18}$;

R^8 and R^{14} are the same or different, and independently are hydrogen or C_{1-5}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkyl-C_{1-5}alkyl, aryl or aryl-C_{1-5}alkyl;

R^6, R^7, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{15}, R^{16}, R^{17} and R^{18} are the same or different, and independently are hydrogen, C_{1-6}alkyl or C_{3-7}cycloalkyl;

r is 1 or 2) or individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R^3 is C_{1-6}alkyl; R^4 is hydrogen or C_{1-6}alkyl;

R^5 is hydrogen or C_{1-6}alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylthio, trifluoromethyl, trifluoromethoxy and $-N(R^{17})R^{18}$ (wherein R^{17} and R^{18} are the same or different, and independently are hydrogen or C_{1-3}alkyl); R^1, R^2 and R^4 are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

3. The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R^3 is C_{1-3}alkyl; R^5 is hydrogen or C_{1-3}alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C_{1-3}alkyl; R^1, R^2 and R^4 are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

4. An antagonist for CRF receptors, comprising a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 3, as an active ingredient.

5. Use of a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 3, for the manufacture of a therapeutic agent as an antagonist for CRF receptors.